|
Drug development in higher-risk myelodysplastic syndromes |
Oct 2024 |
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome |
Apr 2023 |
Blood Cancer |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Hemolysis events in the Phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria |
Apr 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria |
Jun 2024 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
May 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
Dec 2023 |
Blood Advances |
Aplastic Anemia |
